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Introduction
Despite huge scientific efforts, pancreatic ductal adenocarcinoma (PDAC) is still a deadly disease with 5-year survival rate of 6% for all stages combined (1) , and its mortality has not decreased in recent years (2) . This reflects the current absence of prevention, the lack of early diagnosis and screening programs (3) and the low effectiveness of surgical and not surgical treatments for the high local invasion and distant spread and chemoradioresistance (4) . As a result, PDAC may become the second cause of cancer-related death within 2030 (5) . In human, PDAC development occurs through a stepwise process driven by multiple molecular changes with genetic alterations in preinvasive lesions as the full spectrum of pancreatic intraepithelial neoplasia (PanIN1 to 3, from low to high grade of cytological and architectural atypia) or intraductal papillary mucinous neoplasm (IPMN; 6). In the last decades, several genetically engineered mouse models (GEMMs), which strongly mirror the cognate human neoplasia from early carcinogenesis to disease progression, have been established including transgenic, knockin and knockout, and conditional or inducible models (reviewed in [7] ). In comparison with surgical models, a weak point of pancreatic cancer GEMM is heterogeneity with regard to penetrance, latency and growth of neoplasia. Hence, the age of mice is not a reliable and robust parameter to predict the effective clinical stage of pancreatic disease, especially in the early phases of tumorigenesis. This asynchronicity is a strong limitation for chemopreventive, interventional and discovery studies. Indeed, these studies should provide investigations at different time points of the same mouse supposing the tumoral progression but without evidence of a specific tumor stage (8, 9) . Here, to overcome this limitation, we defined an age-independent four-class tumor staging system of pancreatic murine disease using preclinical seven-Tesla magnetic resonance (MR) and ultrasound (US) without contrast agent. We used one of the most widely used GEMM for PDAC, the LSL-Kras G12D/+ ;LSLTrp53 R172H/+ ;Pdx-1-Cre, termed KPC mouse, which closely recapitulates the hallmarks of human PDAC and develops pancreatic cancer in asynchronous manner with 100% penetrance (10) . KPC is characterized by the endogenous expression of mutated Kras G12D and Trp53 R172H in the entire mouse pancreas due to the use of embryonic pancreatic promoter Pdx-1; these two genes are mutated in about 90% (KRAS) and 75% (TP53) of human pancreatic tumors (4) .
Materials and methods

Mouse strain
We used male and female mice carrying mutated Kras G12D and Trp53 R172H under the endogenous pancreatic promoter Pdx-1, LSL-Kras G12D/+ ;LSLTrp53 R172H/+ ;Pdx-1-Cre (KPC; 10; background C57BL/6) provided by Biogem (Avellino, Italy) or by University Hospital and Department of Medicine (Verona, Italy). Pdx-1-Cre (CRE) mice were used as control. All mice were maintained and fed ad libitum in the facility of preclinical imaging of San Raffaele Scientific Institute (Milano, Italy). Mice were monitored three times a week to evaluate their health conditions.
Ethics statement
The study was carried out in compliance with the Animal Care and Use Committee of San Raffaele Scientific Institute (Permit Number: 559). Mouse imaging was performed under general inhalational anesthesia (Isoflurane, 4% for induction and 2% for maintenance in 2 l/min oxygen) as described below. Mice were euthanized by cervical dislocation for histology or when displayed severe clinical symptoms (11) .
Experimental design
Two independent groups of mice were imaged using non-invasive imaging techniques. First cohort, composed by n = 40 KPC and n = 3 CRE mice, was employed as training set to establish a seven-Tesla MR and US imagingbased staging system and to compare imaging and histopathology. Twelve KPC and one CRE were provided by Biogem and 28 KPC and 2 CRE by University Hospital and Department of Medicine. KPC were aged between 2 and 5 months and were evaluated with seven-Tesla magnetic resonance imaging (MRI) and US in a single run after 1 week post their arrival at San Raffaele Scientific Institute; the gross and histopathological examinations were concomitantly performed. The second group was composed by n = 25 KPC mice, which were used to demonstrate the prognostic value of imagebased staging method using seven-Tesla MRI alone; all these KPC were provided by Biogem; MRI was performed at 2, 4 and 6 months.
Preclinical mouse imaging: seven-Tesla MR and US examinations
In vivo examinations were performed under inhalational anesthesia (Isoflurane, 4% for induction and 2% for maintenance in 2 l/min oxygen), with the mice laying on a dedicated temperature control apparatus to prevent hypothermia, having breathing rate and body temperature continuously monitored (SA Instruments, Stony Brook, NY).
During MR acquisitions, mice were placed in prone position into the animal bed for scanning. MRI was performed with a horizontal sevenTesla MR scanner (Bruker, BioSpec 70/30 USR, Paravision 5.1, Germany) equipped with a gradient system characterized by amplitude of 450/675 mT/m, slew rate of 3400/4500 T/m/s and a rise time of 140 ms, coupled with a dedicated volumetric mouse body coil. Axial fat-saturated T2-weighted images (TurboRARE-T2: TR = 3700 ms, TE = 30 ms, spatial resolution = 0.133 × 0.08 mm/pixel, slice thickness = 0.6 mm, gap size = 0, averages = 6) were acquired covering the entire abdominal region.
US examinations were performed using a VEVO 2100 system (FUJIFILM, VisualSonics, Toronto, ON, Canada). US images were acquired in B-mode (brightness mode), using a Vevo2100 linear array transducer (MicroScan MS 550D; 22-55 MHz; FUJIFILM, Visualsonics). Color-Doppler US was eventually performed to assess vascularization of solid components in cystic lesions or to confirm the cystic nature of anechoic alterations (ruling out the presence of vascular malformations).
MR and US images analysis was performed on dedicated workstations, using MIPAV (12) and Vevo Lab 2.2.0 software, respectively, by a senior resident radiologist with the supervision of a radiologist with high experience in clinical and preclinical imaging.
Ex vivo imaging of mouse pancreas using MR
After sacrifice, pancreas was excised, fixed in zinc-formalin (Sigma) overnight and in 70% ethanol for 6 h. Then, it was embedded in 1% agarose gel in a 50 ml polypropylene centrifuge tube (Corning) and scanned with seven-Tesla MR. A 3D RARE T2-weighted sequence (TR/TE = 3000/30 ms, spatial resolution = 0.116 × 0.116 × 0.116 mm/pixel) of the whole specimen was acquired, and AMIRA (version 5.4.0; FEI Visualization Sciences Group) was used to generate 3D reconstructions. Delineation of the pancreas contour was performed semiautomatically although cystic alterations and tumors were manually segmented by the same experienced radiologist that performed the analyses.
Histology and immunohistochemistry
For postmortem histopathology, murine pancreas was isolated, fixed in zinc-formalin (Sigma) and embedded in paraffin. (13, 14) and updated in Baltimore Consensus Meeting for neoplastic precursor lesions in the pancreas (15) . Images were acquired using Aperio AT2 (Leica Biosystems). For automated CK19 and E-cadherin assessment, the entire digital images were analyzed using algorithm macros, and the results were expressed as percentages of strong plus medium positive cells on total cells in stained section.
Statistical analysis
Variables are summarized as mean or median ± SE. Pearson's chi-square test was used to compare proportions. Kruskal-Wallis or Mann-Whitney test was used to compare medians. Survival was evaluated using KaplanMeier analysis, and the significance was estimated using the log-rank test.
Hazard ratios (HRs) were estimated using Cox regression. P value ≤ 0.05 was considered significant. All statistical analyses were performed using SPSS statistical software version 24 (SPSS). Graphs were generated using GraphPad Prism software version 7 (GraphPad Software)
Results
Definition of a four-class tumor staging in KPC mice using MR or US
Healthy CRE pancreas (control) was visualized as an intraperitoneal organ among stomach, duodenum, spleen and left kidney (16,17; Figure 1A ). Forty KPC were imaged with seven-Tesla MR and US, followed by the gross and microscopic examination. We defined four stages of pancreatic neoplastic disease in KPC mice, ranking from the earliest stage 1 to the stage 4. For each stage, representative MR and US images, three-dimensional reconstructions and gross appearance are shown ( Figure 1A ). Stage 1 was defined as normal pancreatic parenchyma without any imaging-detectable alteration: as healthy pancreas in CRE mouse, it was homogeneously isohypointense at MRI and homogeneously isohyperechoic at US, without any focal lesion ( Figure 1A and B). Stage 2 was characterized by signal heterogeneity due to the presence of focal or diffuse cystic alterations (markedly hyperintense at MRI; anechoic at US) without any detectable solid component or vascularized (at Doppler US) mural nodule ( Figure 1A and B). Stage 3 was defined by the presence of at least one pancreatic nodule up to 5 mm of diameter, heterogeneous and ill-defined, slightly hyperintense at MR and hypointense at US with intrinsic Doppler signals ( Figure 1A and B and Supplementary Figure 1A , available at Carcinogenesis Online); the solid nodule could present cystic components ( Figure 1B ). The presence of at least one solid lesion ≥5 mm in diameter identified the stage 4 ( Figure 1A ). The remaining non-tumor parenchyma of stages 3 and 4 could be normal (Supplementary Figure 1B , available at Carcinogenesis Online) or could present typical alterations of stage 2. Ascites and signs of altered bowel (i.e. occlusion, swelling) could be observed in stage 4. Liver metastases were never detected. Tissue alterations measurements were consistent between MR and US analyses ( Figure 1A) . In Table 1 
Histopathological validation of the four-class tumor staging in KPC mice
Immediately after image-based staging, mice were killed for histopathological examination. Pancreas of CRE mice (control) is a normal murine pancreas, characterized by abundance of normal acinar tissue, presence of scattered islets of Langerhans and few CK19+ normal ducts (Figure 2A and B) . The 66.7% (2/3) of KPC at stage 1 displayed multiple foci of low-and high-grade mPanINs in a context of healthy pancreatic tissue ( Figure 2A) ; in a single case of stage 1 KPC, we detected a normal pancreas (Table 1 ). Besides PanINs, stage 2 was marked by multifocal cystic papillary neoplasms ( Figure 2A and Table 1 ). PDAC was present in all stages 3 and 4, associated with widespread architectural changes and diffuse low-and high-grade mPanINs in surrounding tissue ( Figure 2A and Table 1 ). The same trend was noted for acinar-to-ductal metaplasia (P = 0.098; Table 1 and Supplementary Figure 3 , available at Carcinogenesis Online). As expected, strong and medium CK19+ cells significantly increased from stages 1 to 4 ( Figure 2B and Supplementary Figure 4 , available at Carcinogenesis Online). Membranous staining of E-cadherin is robust in CRE mice ( Figure 2C ) although there was no nuclear Trp53 staining ( Figure 2D) . Conversely, as a function of staging, E-cadherin was less expressed by transformed cells ( Figure 2C and Supplementary Figure 4 , available at Carcinogenesis Online); moreover, some cells of precursor alterations and the majority of PDAC cells showed an intense expression of Trp53 ( Figure 2D ). Fibrosis, as profuse deposition of collagen in extracellular matrix, was displayed peri-PanINs and peri-cystic papillary neoplasms (stages 1 and 2) and intratumors (stages 3 and 4; Figure 2E ), but not surrounding tumors.
The imaging-based four-class tumor staging is correlated to survival of KPC mice
In order to determine the prognostic impact of imaging-based staging on survival, we carried out three scheduled imaging sessions at 2, 4 and 6 months of age on the second cohort of n = 25 KPC (Table 2) . Imaging was performed for n = 18 mice at 2 months, n = 24 mice at 4 months and n = 15 mice at 6 months. The median overall survival time was 216 days ( Figure 3A) ; no sex-related difference was observed (median ± SE in days, 201 ± 39.1 versus 216 ± 47.3, male versus female, respectively, P = 0.930, long-rank test). At month 2, 61% (11/18) of monitored KPC was stage 1 and 39% (7/18) was stage 2 (Table 2 and Figure 3B ). At month 4, the distribution of studied KPC among stages was as follows: 33% (8/24) stage 1, 37% (9/24) stage 2, 13% (3/24) stage 3 and 17% stage 4 (4/24; Table 2 and Figure 3B ). Figure 3B ). Kaplan-Meier analysis revealed that regardless age, the overall survival time worsens along with the increasing of the stage (Table 2 and Figure 3C ). Univariate Cox regression analysis confirmed tumor stage as a relevant risk factor for PDAC mortality at every time points: at 2 months, HR = 4.683 (95% CI: 1.313-16.699, P = 0.017); at 4 months, HR = 3.971 (95% CI: 2.140-7.368, P < 0.001) and at 6 months, HR = 6.590 (95% CI: 2.633-16.496, P = 0.001). Again, there was no difference in the stage-specific median survival time from diagnosis if KPC was classified as stage 1 at 2, 4 and 6 months: 237 ± 13.4, 191 ± 116, 319 ± 192 days, respectively (P = 0.980, long-rank test; Figure 3D ). For stage 2, the time of survival from diagnosis at 2, 4 and 6 months was similar:
101 ± 3.9, 95 ± 31.1, 84 days, respectively (P = 0.679, long-rank test; Figure 3D ). Likewise, the survival time from diagnosis was similar at 4 and 6 months for overt PDAC: 68 ± 12.2 and 85 ± 45.7 days, respectively for stage 3 (P = 0.694, long-rank test), 35 ± 11 and 5 ± 10.5 days, respectively for stage 4 (P = 0.855, long-rank test; Figure 3D ).
Discussion
In pancreatic oncological field, GEMMs offer the great opportunity to explore, e.g. drug delivery, therapeutic target discovery, cancer biology, environmental risk factors and biomarker expression. One of the most known GEMM of pancreatic cancer is the LSL-Kras G12D/+ ;LSL-Trp53 R172H/+ ;Pdx-1-Cre. KPC recapitulates the development of cognate human PDAC, from the appearance of the most common precursor PanIN to invasive pancreatic cancer (10) . Research studies were often carried out at certain age of mouse to analyze early or overt cancer (8,9), but it was unclear which animals have already developed tumors. Indeed, it is well known and also shown in this study that in KPC model, the onset of preneoplastic lesions and PDAC is not age-related. The asynchronicity of PDAC development in KPC mice has potential explanations. A constant KRAS oncogenic pressure is present, and the point mutation of Trp53 R172H carries out the loss of heterozygosis at wild-type locus; these two events sustain the chromosomal instability (10) . Owing to spontaneous additional genetic alterations over time, some KPC mice may have a strong or mild aggressive tumor phenotype that promotes or slows down the PDAC progression (9, 18) . In addition, crosstalk between tumor and microenvironment sustains the interindividual differences (19) . Finally, it is also noteworthy that pancreatic tumor arises with variable latency in KPC (10) . Hence, the enrollment of animals harboring the tumor at the same stage and sharing the same clinical outcome is challenging. The imaging technologies have been extensively applied to assess tumor mass and activity, as reported previously (17, (20) (21) (22) . In this study, we defined an imaging-based staging system for PDAC in the LSL-Kras G12D/+ ;LSL-Trp53 R172H/+ ;Pdx-1-Cre, and we demonstrated its relationship with overall survival. We were able to define in vivo age-independent four-class staging system using high-resolution preclinical dedicated seven-Tesla MR and US, without any tracer agents. The staging system ranked from stages 1 to 4; stages 1 and 2 identified mice with premalignant pancreatic alterations although stages 3 and 4 detected an overt PDAC, respectively <5 mm and ≥5 mm in diameter. The stages were firstly defined by imaging techniques and then histopathological characterized. The size of tissue alterations could be measured, and we reconfirmed that the non-invasive monitoring is feasible in the same mouse over time (17, 23, 24) . Moreover, radiologically detectable tumor mass was a frank adenocarcinoma in KPC mice at stages 3 and 4; indeed, in PDAC nodule, most of fibrosis was localized intratumor and there was not a thick collagen bundle, which could have contributed to the tumor mass, in close proximity to PDAC. In the future, in addition to histopathological evaluation, other in vivo imaging techniques (e.g. multiparametric MRI or contrast-enhanced US) could be performed to better characterize this intratumoral desmoplastic component. For instance, very recently in three different PDAC models (subcutaneous, orthotopic and KPC), the degree of fibrosis was demonstrated to correlate with magnetization transfer suppression ratios and apparent diffusion coefficient (25) . The use of MR and US required the presence of specific infrastructures and the availability of technical expertise dedicated to preclinical research. MR has superior soft-tissue and intrinsic contrast resolution; exploiting this feature, without any contrast agent, we localized pre-and neoplastic alterations embedded in soft murine pancreas and we were able to generate ex vivo 3D reconstruction. Moreover, MR is not operator-dependent and offers a panoramic view of the abdomen. MR has the possibility to record images of body sections (not only of pancreatic tissue) that may be retrospectively re-evaluated. US is extremely cost and time effective, and its spatial resolution is definitely higher than seven-Tesla MR. However, US has a limited field of view and depth of penetration. Additionally, US performance is investigator-dependent, lacks the panoramic evaluation and suffers from acoustic shadowing of the gastrointestinal tract. We made a comparison into groups based on their stage at 2, 4 and 6 months of age. P value was estimated by log-rank test. (D) Kaplan-Meier plots of stage-specific time to death from diagnosed. KPC mice were divided into groups based on the time point of staging (2, 4 and 6 months of age). P value was estimated by log-rank test.
to be detected at MR and US with our simple imaging protocol; hence stage 1 KPC was defined as mouse having radiologically healthy pancreas, same as CRE mice. Stages 1 and 2 identified low-and high-grade mPanINs and cystic papillary neoplasms (besides mPanINs), respectively. At this time, the detection and monitoring of mPanIN lesions were feasible using other imaging techniques, such as PET-CT (26) , molecular imaging system with selective or target-specific fluorescent probe (27) (28) (29) and hyperpolarized 13C MR spectroscopy imaging (30) . In only two cases of stage 2, cystic papillary neoplasms were not detected at histopathology, probably due to the limited plane of sections, whereas imaging permits a complete view of the organ. All mice in stages 1 and 2 showed acinar-to-ductal metaplasia but, same as mPanINs, such alteration could not be detected either by fat-saturated T2-weighted MR sequences or by US. It has been widely described that mPanINs, cystic papillary neoplasms, acinar-to-ductal metaplasia and IPMN resemble human precursors of PDAC (10, 31) . Therefore, lower prevalence of precursor lesions in late stage of disease (3 and 4) could be explained as the murine PDAC in KPC evolving not only from mPanINs but also from other premalignant lesions through a tumorigenic process. As expected, PDAC in stages 3 and 4 has a predominantly glandular pattern with strong staining for CK19 (ductal marker) and Trp53 (means loss of wild-type allele). The expression of the epithelial marker E-cadherin correlates with the differentiation state of PDAC (10, 32) ; the loss of this marker characterizes stage 3 but mostly stage 4. To further validate the accuracy of our staging system, we evaluated the impact of staging on prognosis of KPC. We demonstrated a reduction of overall survival along with the increase of the stage. Again, the stage is a statistically significant risk factor for mortality of KPC. Overall data showed the fourclass tumor staging is an age-independent tool to synchronize PDAC progression in KPC mice. As a result, mice having the same stage but different ages can be enrolled in the same group for chemoprevention, intervention and discovery settings because they share specific pathological features. Furthermore, each KPC mouse can be repeatedly analyzed and contributed to experimental data in stage-dependent manner. Our approach overcomes the enrollment criterion based on age and improves one based on the presence of cancer only. Interestingly, the stage 2 defined a stage of radiologically detectable premalignant alterations without manifest clinical symptoms; hence, stage 2 is the most promising for preclinical studies of early diagnosis and prevention. From all these perspectives, the number of required mice for all types of preclinical studies can be reduced according to the 3R principle. In conclusion, the non-invasive four-class tumor staging based on imaging is able to define effective and simple in vivo protocols to grade the tumor progression in KPC mice, paying crucial attention to early and clinical asymptomatic phases.
